川宁生物：2025年前三季度整体期间费用同比上升26%

Core Viewpoint - Chuaning Bio announced an increase in overall period expenses by 26% year-on-year for the first three quarters of 2025, primarily driven by rising R&D costs due to new product development and trial runs [2] Group 1: Financial Performance - R&D expenses saw a significant increase as the company focused on new product technology development and utilized some production lines for trial runs [2] - Financial expenses decreased notably due to the company's efforts to reduce interest-bearing debt, leading to lower interest expenses [2] - Sales expenses experienced a slight decline, attributed to reduced overseas commission payments [2] Group 2: Future Outlook - The company anticipates a downward trend in expenses for the fourth quarter compared to the first three quarters, as the latter included various one-time expenses that will not recur in Q4 [2] - As new products gradually enter production, trial costs are expected to decrease, and the ongoing reduction of interest-bearing debt will further lower expenses in Q4 [2] - The company plans to maintain expense control measures from Q4 into the following year to enhance operational efficiency and ensure that strategic investments translate into long-term profitability and core competitiveness [2]